138 related articles for article (PubMed ID: 37468684)
1. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trial (ONWARD-DPP4 Study).
Ishii H; Kamei N; Shimono D; Niiya T; Tosaki T; Kitazawa T; Suzuki D; Wakasa Y; Seino H; Oishi M; Ohashi H; Higami K; Akai H;
Diabetes Ther; 2023 Oct; 14(10):1639-1658. PubMed ID: 37468684
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes.
Kawasaki E; Nakano Y; Fukuyama T; Uchida A; Sagara Y; Tamai H; Tojikubo M; Hiromatsu Y; Koga N
World J Diabetes; 2021 Dec; 12(12):2087-2095. PubMed ID: 35047122
[TBL] [Abstract][Full Text] [Related]
3. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study.
Yoshizawa Y; Hosojima M; Kabasawa H; Tanabe N; Ugamura D; Koda Y; Shimada H; Takasawa T; Ito T; Kitamura T; Kobayashi M; Suzuki Y; Narita I; Saito A
Diabetes Ther; 2021 Mar; 12(3):655-667. PubMed ID: 33474645
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
Gantz I; Okamoto T; Ito Y; Sato A; Okuyama K; O'Neill EA; Engel SS; Lai E;
Diabetes Ther; 2017 Aug; 8(4):793-810. PubMed ID: 28589493
[TBL] [Abstract][Full Text] [Related]
5. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
[TBL] [Abstract][Full Text] [Related]
6. Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Gantz I; Sokolova L; Jain L; Iredale C; O'Neill EA; Wei Z; Lam R; Suryawanshi S; Kaufman KD; Engel SS; Lai E
Clin Ther; 2017 Oct; 39(10):2024-2037. PubMed ID: 28923291
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.
Kadowaki T; Seino Y; Kaku K; Okamoto T; Kameya M; Sato A; Hirano T; Oshima N; Gantz I; O'Neill EA; Engel SS;
Diabetes Obes Metab; 2021 Jun; 23(6):1242-1251. PubMed ID: 33512755
[TBL] [Abstract][Full Text] [Related]
8. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
Oita M; Miyoshi H; Ono K; Nakamura A; Cho KY; Nomoto H; Yamamoto K; Omori K; Manda N; Kurihara Y; Aoki S; Atsumi T
Endocr J; 2018 Feb; 65(2):141-150. PubMed ID: 29093280
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Home P; Shankar RR; Gantz I; Iredale C; O'Neill EA; Jain L; Pong A; Suryawanshi S; Engel SS; Kaufman KD; Lai E
Diabetes Res Clin Pract; 2018 Apr; 138():253-261. PubMed ID: 29079379
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility and Validity of a Questionnaire Measuring Treatment Burden on Patients with Type 2 Diabetes: Diabetic Treatment Burden Questionnaire (DTBQ).
Ishii H; Shin K; Tosaki T; Haga T; Nakajima Y; Shiraiwa T; Watanabe N; Koizumi M; Nakajima H; Okada S; Mashitani T; Mohri T; Akai Y
Diabetes Ther; 2018 Jun; 9(3):1001-1019. PubMed ID: 29600503
[TBL] [Abstract][Full Text] [Related]
12. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
[TBL] [Abstract][Full Text] [Related]
14. Omarigliptin for the treatment of type 2 diabetes mellitus.
Evans PM; Bain SC
Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
[TBL] [Abstract][Full Text] [Related]
16. Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor.
Ishii H; Suzaki Y; Miyata Y; Matsui S
Diabetes Ther; 2019 Aug; 10(4):1369-1380. PubMed ID: 31214997
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
19. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
20. Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).
Ishii H; Nakajima H; Kamei N; Niiya T; Hiyoshi T; Hiramori Y; Ohtsu S; Noto T; Shimono D
Diabetes Ther; 2020 Dec; 11(12):2959-2977. PubMed ID: 33057967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
